S-606001

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

10 competitors in Pompe Disease

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Approved

32

Trexall

Jazz Pharmaceuticals

Approved

23

Lumizyme

GGenzyme, a Sanofi Company

Approved

134

Velcade

SShilpa Grover, MD, MPH

Approved

15

Avalglucosidase Alfa

Sanofi

Phase 2

26

Neupogen

EEastern Cooperative Oncology Group

Preclinical

17

S-606001

Shionogi

Phase 2

3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pompe Disease3 trials

A Phase 1b, Multicenter, Single-arm, Open-label Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of S-606001 as a Monotherapy in Adult Patients With Late-onset Pompe Disease

Not yet recruiting·Shionogi·Phase 1·NCT07787650·15 enrolled

A Phase 2, Open-label, Multicenter, Extension Study to Investigate the Long-term Safety and Efficacy of S-606001 in Patients With Late-onset Pompe Disease

Not yet recruiting·Shionogi·Phase 2·NCT07750990·60 enrolled

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Pharmacodynamics, and Preliminary Efficacy of S-606001 as an Add-on to Enzyme Replacement Therapy in Patients With Late-onset Pompe Disease

Recruiting·Shionogi·Phase 2·NCT07123155·45 enrolled

Details

Drug Info

Related News